Different Angiogenic Pathways Characterize Superficial and Invasive Bladder Cancer

Cancer Research

Volumn 55, Issue 3, 1995, Pages 510-513

  O'Brien, Tim ^a,b,c   Cranston, David ^c   Fuggle, Susan ^b   Bicknell, Roy ^a   Harris, Adrian L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR RECEPTOR; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; RIBONUCLEASE; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PREDICTION; PRIORITY JOURNAL;

ANTISENSE ELEMENTS (GENETICS); BLADDER; BLADDER NEOPLASMS; COMPARATIVE STUDY; ENDOTHELIAL GROWTH FACTORS; HUMAN; LYMPHOKINES; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; REFERENCE VALUES; RESTRICTION MAPPING; RIBONUCLEASES; SUPPORT, NON-U.S. GOV'T; THYMIDINE PHOSPHORYLASE;

EID: 0028961523     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Folkman, J. What is the evidence that tumours are angiogenesis dependent? N. Engl. J. Med., 285: 82–86, 1990.
2. Dickinson, A., Fox, S., Persad, R., Hollyer, J., Sibley, G., and Harris, A. L. Quantitation of angiogenesis is an independent predictor of prognosis in invasive bladder cancer. Br. J. Urol., in press, 1995.
3. Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E. N., Moore, D. H., Meli, S., and Gasparini, G. Tumour angiogenesis. A new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst., 84: 1875–1887,1992.
4. Horak, E. R., Leek, R., Klenk, N., Le Jeune, S., Smith, K., Stuart, N., Greenall, M., and Harris, A. L. Angiogenesis assessed by platelet/endothelial cell adhesion molecule antibodies, as an indicator of node metastasis and survival in breast cancer. Lancet, 340: 1120–1124, 1992.
5. Srivastava, A., Laidler, P., Davies, R., Horgan, K., and Hughes, L. E. The prognostic significance of rumour vascularity in intermediate-thickness (0.76–4 mm thick) skin melanoma. Am. J. Pathol., 133: 419–423, 1988.
6. Vesalainen, S., Lipponen, P., Talja, M., Alhava, E., and Syrjanen, K. Tumour vascularity and basement membrane structure as prognostic factors in T12M0 prostatic adenocarcinoma. Anticancer Res., 14: 709–714, 1994.
7. Wakui, S., Furusato, M., Itoh, T., Sasaki, H., Akiyama, A., Kinoshita, I., Asano, K., Tokuda, T., Aizawa, S., and Ushigoma, S. Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J. Pathol., 168: 257–262, 1992.
8. Folkman, J., and Shing, Y. Angiogenesis. J. Biol. Chem., 267: 10931–10934, 1992.
9. Bicknell, R., and Harris, A. L. Novel growth regulatory factors and tumour angiogenesis. Eur. J. Cancer, 27: 781–785, 1991.
10. Takahashi, A., Sasaki, H., Kim, S., Tobisu, K., Kakizoe, T., Tsukamato, T., Kuma-mato, Y., Sugimura, T., and Terada, M. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res., 54: 4233–4237, 1994.
11. Ravery, V., Jouanneau, J., Gil-Diez, S., Abou, C., Caruelle, J., Barritault, D., and Chopin, D. Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma. Urol. Res., 20: 211–214, 1992.
12. Chopin, D. K., Caruelle, J. P., Colombel, M., Palcy, S., Raver, V., Caruelle, D., Abou, C. C., and Barritault, D. Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J. Urol., 150: 1126–1130, 1993.
13. Nguyen, M., Watanabe, H., Budson, A., Richie, J., and Folkman, J. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J. Natl. Cancer Inst., 85: 241–242, 1993.
14. Brown, L., Berse, B., Jackman, R., Tognazzi, K., Manseau, E., Dvorak, H., and Senger, D. Increased expression of vascular permeability factor (VEGF) and its receptors in kidney and bladder cancers. Am. J. Pathol., 143: 1255–1262, 1993.
15. Ferrara, N. Vascular endothelial growth factor. TCM, 3: 244–250, 1993.
16. Kondo, S., Asano, M., and Suzuki, H. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumour growth, and its inhibition by the antibody. Biochem. Biophys. Res. Commun., 194: 1234–1241, 1993.
17. Zhang, H-T., Craft, P., Scott, P., Ziehe, M., Weich, H., Harris, A. L., and Bicknell, R. Expression of vascular endothelial growth factor in MCF-7 cells enhances tumour growth and vascular density. J. Natl. Cancer Inst., in press, 1995.
18. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (Lond.), 362: 841–844, 1993.
19. Ishikawa, F., Miyazono, K., Hellman, U., Drexler, H., Wernstedt, C., Hagiwara, K., Usuki, K., Takaku, F., Risau, W., and Heldin, C. H. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature (Lond.), 338: 557–562, 1989.
20. Furukawa, T., Yoshimura, A., Sumizawa, T., Haraguchi, M., and Akiyama, S. Angiogenic factor. Nature (Lond.), 356: 668, 1992.
21. Moghaddam, A., and Bicknell, R. Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine Phosphorylase activity. Biochemistry, 31: 12141–12146, 1992.
22. Yoshimura, A., Kuwazuru, Y., Furukawa, T., Yoshida, H., Yamada, K., and Akiyama, S. Purification and tissue distribution of human thymidine Phosphorylase; high expression in lymphocytes, reticulocytes and tumors. Biochim. Biophys. Acta, 1034: 107–113, 1990.
23. Zimmerman, M., and Seidenberg, J. Deoxyribosyl transfer I. Thymidine Phosphorylase and nucleoside deoxyribosyltransferase in normal and malignant tissues. J. Biol. Chem., 239: 2618–2621, 1964.
24. Reynolds, K., Farzaneh, F., Collins, W. P., Campbell, S., Bourne, T. H., Lawton, F., Moghaddam, A., Harris, A. L., and Bicknell, R. Correlation of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J. Natl. Cancer Inst., 86: 1234–1238, 1994.
25. Pauly, J. L., Schuller, M. G., Zelcer, A. A., Kirss, T. A., Gore, S. S., and Germain, M. J. Identification and comparative analysis of thymidine Phosphorylase in the plasma of healthy subjects and cancer patients. J. Natl. Cancer Inst, 58: 1587–1590,1977.
26. Moghaddam, A., Zhang, H-T., Fan, T-P., Hu, D-E., Lees, V. C., Turley, H., Fox, S. B., Gatter, K. C., Harris, A. L., and Bicknell, R. Thymidine Phosphorylase is angiogenic and promotes tumor growth. Proc. Natl. Acad. Sei. USA, in press, 1995.
27. Haraguchi, M., Kazutaka, M., Uemura, K., Sumizawa, T., Furukawa, T., Yamada, K., and Akiyama, S-I. Angiogenic activity of enzymes. Nature (Lond.), 368: 198, 1994.
28. Heney, N., Ahmed, S., and Flanagan, M. Superficial bladder cancer: progression and recurrence. J. Urol., 130: 1083–1086, 1983.
29. Heney, N., Proppe, K., and Prout, G. J. Invasive bladder cancer: tumour configuration, lymphatic infiltration and survival. J. Urol., 130: 895–897, 1983.
30. Raghavan, D., Shipley, W., Garnick, M., Russell, P., and Richie, J. The biology and management of bladder cancer. N. Engl. J. Med., 322: 1129–1138, 1990.
31. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid gua-nidium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162:156–159,1987.
32. Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarawicz, D., Fiddes, J., and Abraham, J. The human gene for vascular endothelial growth factor. J. Biol. Chem., 266: 11947–11954, 1991.
33. McCarthy, S. A., and Bicknell, R. Responses of pertussis toxin-treated microvascular endothelial cells to transforming growth factor b,. J. Biol. Chem., 267:21617–21622, 1992.
34. Dalbagni, G., Presti, J., Reuter, V., Fair, W. R., and Cordon, C. C. Genetic alterations in bladder cancer. Lancet, 342: 469–471, 1993.
35. Spruck, C., III, Ohneseit, P. F., Gonzalez, Z. M., Esrig, D., Miyao, N., Tsai, Y. C., Lerner, S. P., Schmutte, C., Yang, A. S., Cote, R., Dubeau, L., Nichols, P., Hermann, G., Steven, K., Horn, T., Skinner, D., and Jones, P. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res., 54: 784–788, 1994.
36. Orlow, L., Lianes, P., Lacombe, L., Dalbagni, G., Reuter, V. E., and Cordon-Cardo, C. Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. Cancer Res., 54: 2848–2851, 1994.
37. Knowles, M. A., Elder, P. A., Williamson, M., Cairns, J. P., Shaw, M. E., and Law, M. G. Allelotype of human bladder cancer. Cancer Res., 54: 531–538, 1994.
38. Habuchi, T., Takahashi, R., Yamada, H., Kakehi, Y., Sugiyama, T., and Yoshida, O. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet, 342: 1087–1088, 1993.
39. Bicknell, R., and Harris, A. L. Anticancer strategies involving the vasculature: vasculature targetting and the inhibition of angiogenesis. Semin. Cancer Biol., 3: 399–407, 1992.